Speaker Profile
MS, CEO, Varosync
Biography
Harry Kabodha is a computational researcher who founded Varosync to solve a fundamental problem he identified during his graduate work at Columbia's Irving Institute for Cancer Dynamics: the entire drug industry designs for static, 3D proteins in a 4D, dynamic world. He has assembled a team of elite engineers and scientists to build a new computational paradigm. His mission is to unlock a new class of safer, more precise medicines by systematically designing for functional selectivity.
Talk
From Genomic Precision to Functional Precision
Genomic precision tells us what to target, but not how. We present a dynamic AI engine that models protein motion to find cryptic allosteric sites. This unlocks functional selectivity, enabling the design of "molecular scalpels" that avoid the "black box" side effects of current "blunt instrument" drugs.
AI for Emerging Therapeutics Showcase:
Varosync
Varosync is a technology company building a dynamic AI engine that models protein motion to systematically discover the cryptic allosteric sites required to engineer functionally selective small molecules through biased signaling.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 AI for Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies to explore the transformative role of artificial intelligence in accelerating the discovery, development, and optimization of novel therapeutic modalities. From predictive algorithms for drug efficacy to real-time analysis in clinical trials, AI is revolutionizing the way we approach emerging therapies, including RNA-based treatments, gene editing, and personalized medicine. Industry leaders and experts will discuss AI-driven advancements, collaborative frameworks, and the challenges of integrating cutting-edge technologies into therapeutic innovation. Join us for an in-depth look at how AI is shaping the future of breakthrough therapeutics.
